TECHWIRE 30
(CIX: WRAL30)  1,059.57  down arrow-0.48  (-0.05 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Apple)  102.99  up arrow+0.52  (0.51 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: QUINTILES)  56.55  up arrow+0.05  (0.09 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: BASF SE)  87.84  down arrow-1.17  (-1.31 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: BioCryst)  11.70  up arrow+0.33  (2.9 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: BioDelivery)  15.90  down arrow-0.45  (-2.75 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: CEMP)  11.88  down arrow-0.31  (-2.54 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Cisco Systems)  23.26  down arrow-0.25  (-1.06 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Cree)  27.28  down arrow-5.87  (-17.71 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: DARA)  0.90  up arrow+0.03  (3.44 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: EMC CORPORATION)  27.37  up arrow+0.17  (0.63 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Extreme Networks)  3.01  down arrow-0.19  (-5.94 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: FB)  78.37  down arrow-0.32  (-0.41 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: GLAXOSMITHKLINE)  44.41  up arrow+0.78  (1.79 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: GOOG)  532.71  up arrow+6.17  (1.17 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: IBM)  161.79  down arrow-1.44  (-0.88 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NY: LH)  101.07  down arrow-0.23  (-0.23 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: Lenovo Group)  28.95  down arrow-0.07  (-0.24 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: MRK)  55.51  up arrow+0.38  (0.69 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Microsoft Corp)  44.38  down arrow-0.5  (-1.11 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: NTAP)  39.66  up arrow+0.39  (0.99 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: NOVARTIS AG)  88.20  down arrow-0.41  (-0.46 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: Novozymes A/S)  40.92  down arrow-0.17  (-0.4 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: PFIZER)  28.30  up arrow+0.02  (0.07 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Pozen)  8.47  up arrow+0.2  (2.42 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: RED HAT)  54.80  down arrow-2.33  (-4.08 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: BBRY)  9.89  down arrow-0.26  (-2.56 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Salix)  137.61  down arrow-2.94  (-2.09 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: SQI)  15.21  down arrow-0.12  (-0.78 %)  Updated: 08:10 PM EDT, Oct 22 2014

Posts tagged “Salix”

Updated October 8

Lenovo class-action suit; new GSK probe; AT&T data breach; Salix drug wins OK; Facebook's anonymous app; Lenovo-NEC deal

Bulldog In today's Bulldog blog wrapping up the latest technology and life science news: Lenovo settles a class-action suit over Wi-Fi; GSK faces another bribery investigation; AT&T data breach; FDA OKs Salix colitis treatment; Facebook is developing an app for anonymous posts; and Lenovo extends its partnership with NEC.

Updated October 3

Salix calls off $2.7B merger, cites US tax policy; stock surges

Salix    Salix Pharmaceuticals says a tougher U.S. tax policy against merger deals designed to lower taxes by moving companies overseas is why a $2.7 billion merger with Italy's Cosmo Pharmaceuticals is being called off. The deal will cost Salix a $25 million termination fee.

Updated September 24

$10B deal? Sale talk drives Salix shares to record high

Salix    Raleigh-based Salix Pharmaceuticals is talking a possible deal with Allergan, according to multiple media reports. A deal would be worth $10 billion or more as speculation drives up the price of Salix shares to a record high.

September 23

Cisco execs sell $19M in shares; Nortel trial nears end; GSK launches 2 startups; Salix $100M settlement; AT&T Amazon bundle

Bulldog In today's wrapup of tech and life science news: Several Cisco executives sell $19 million in shares; Nortel's huge bankruptcy trial nears end; GSK launches two startups; Salix reaches a $100M settlement; and AT&T's new entertainment bundle includes Amazon Prime.

August 20

Premium Lock Uber hires Obama exec; Salix near deal close; Ballmer leaves Microsoft board; Lenovo's NFL Fantasy; HTC's new phone

Bulldog In today's Bulldog roundup of tech and life science news: Uber hires former Obama exec to help with lobbying; Salix nears deal close; Ballmer quits Microsoft board; Lenovo's new NFL Fantasy contest; HTC's new phone runs Windows.

July 17

Premium Lock Salix wins FDA approval for drug to treat rare genetic disorder

Salix Raleigh-based Salix Pharmaceuticals has received FDA approval for a drug to treat a rare genetic disorder called hereditary angloedema.

Updated July 10

Premium Lock Salix stock sags despite merger deal that boosts drug pipeline, lowers tax rate

If investors are fretting, it could be because Salix shareholders will be on the hook for taxes they weren't expecting to pay. The company notes in its securities filings that the conversion of Salix stock into Salix plc stock is considered a taxable event, meaning all Salix shareholders will owe taxes when the deal closes even if they don't sell their shares. Learn more about the deal.

Salix Salix

July 9

Premium Lock Salix to merge with Ireland unit of Cosmo Pharma in stock deal

Salix Pharmaceuticals (NASDAQ:SLXP) is merging with a subsidiary of Italian drug company Cosmo Pharmaceuticals in a deal that brings Salix new drug products and also reduces the Raleigh company's taxes.

Salix Salix

Updated February 27

Premium Lock Salix strikes $12M licensing deal for bowel prep drug

Salix    Raleigh-based Salix Pharmaceuticals, which focuses on gastrointestinal treatments, is adding another product to its lineup. Salix is committing $12 million plus royalties to RedHill Biopharma for a bowel prep drug.

February 25

Premium Lock Salix prevails in $150M suit filed by drug partner

Salix In a legal fight dating to 2011, Raleigh-based Salix Pharmaceuticals has won a jury decision that throws out a lawsuit filed against it by drug partner Napo Pharmaceuticals.

January 30

Premium Lock FDA accepts new drug filing for Salix rectal inflammation drug

Salix A proposed treatment for a difficult to threat form of rectal inflammation licensed by Salix Pharmaceuticals is moving closer to approval by the FDA.

Updated January 14

Premium Lock Expanding Salix sales force expected to grow drug sales to $1.6B in 2014

Salix Salix Pharmaceuticals expects it will reach $1.6 billion in total product revenue this year. WRALtechWire Insiders can read more details on the gastrointestinal pharma's projections following the close of its $2.8 billion acquisition of Santarus as its stock hits a new record high.

January 3

Premium Lock Salix closes on $2.6B deal for San Diego pharma Santarus

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

Updated November 7, 2013

Premium Lock Salix to acquire San Diego pharma Santarus for $2.6B

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

August 8, 2013

Premium Lock Salix CEO Logan talks about M&A strategy

Salix Even though Salix Pharmaceuticals has diversified its portfolio of gastrointestinal drug treatments, CEO Carolyn Logan says Salix is always looking for deals. Read what she has to say about Salix's acquisition strategy.

Updated June 11, 2013

Premium Lock Salix constipation drug Relistor to go before FDA advisory panel

Salix Salix Pharmaceuticals' (NASDAQ:SLXP) constipation drug Relistor, which failed to win regulatory approval last year, will be up for review by a FDA advisory committee.

May 22, 2013

Premium Lock Salix rectal inflammation drug shows positive clinical trial results

Salix Salix Pharmaceuticals' topical foam to treat rectal inflammation could be filed for approval with the Food and Drug Administration by the end of September.

Updated May 10, 2013

Premium Lock Prescription growth lifts Salix's 1Q sales

Salix First quarter sales of Salix Pharmaceuticals' top drug, Xifaxan, increased 18 percent year over year. Read more about the company's performance.

Updated May 10, 2013

Premium Lock FDA makes Salix wait on constipation drug; company says no new trials needed

Salix The FDA said it needed more data to approve expanded use of Salix Pharmaceutical's constipation drug Relistor. Read why Salix thinks it has enough information.

Updated March 6, 2013

Premium Lock Salix CEO gears for federal probe that could go on for 'quite some time'

Salix Carolyn Logan, chief executive officer at Raleigh-based Salix pharmaceuticals, and the company are gearing up for what could be a lengthy federal investigation into its marketing practices.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll